Exchange: NASDAQ·Updated 04:05 AM EDT
BEAM logo

BEAM Beam Therapeutics Inc

$24.57
$0.20
(0.82%)
Pre-Market
Prev Close $24.37
EarningsNov 3
Mkt Cap$2.68B
Vol1,309.00

About BEAM

Beam Therapeutics, Inc. is a biotechnology company, which engages in the establishment of integrated platform for precision genetic medicines. Its pipeline includes BEAM-101, BEAM-302, Engineered Stem Cell Antibody Paired Evasion (ESCAPE), BEAM-301, and BEAM-201. The company was founded by David R. Liu, Feng Zhang, Alexis Komor, Nicole Gaudelli, and J. Keith Joung on January 25, 2017 and is headquartered in Cambridge, MA.
44

Bearish Sentiment

How do you feel about BEAM?

Advertisement|Remove ads.